Record 1H FY26 revenue of $17.1 million was driven by 73% US growth and expanding recurring revenues. Short-term US installation targets were deferred due to guideline publication delays, but medium-term growth prospects remain strong.Original document: Cyclopharm Limited [CYC] Earnings Release — S…
Record 1H FY26 revenue of $17.1 million was driven by 73% US growth and expanding recurring revenues. Short-term US installation targets were deferred due to guideline publication delays, but medium-term growth prospects remain strong.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.